<DOC>
	<DOCNO>NCT01850680</DOCNO>
	<brief_summary>Primary Objective : To assess safety tolerability single dose subcutaneously administer sarilumab Japanese patient rheumatoid arthritis ( RA ) receive concomitant treatment methotrexate . Secondary Objective : To assess pharmacokinetic profile single subcutaneous ( SC ) dose sarilumab Japanese RA patient .</brief_summary>
	<brief_title>Single Ascending Dose Study Safety Tolerability Sarilumab Methotrexate Japanese Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Total study duration per patient 88 day 1 . Screening : 3 28 day 2 . Treatment : 1 day 3 . Follow-up : 57± 3 day dose</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female Japanese 20 65 year age 2 . Diagnosis rheumatoid arthritis ( RA ) ≥ 3 month duration 3 . Treated minimum 8 week Methotrexate ( MTX ) stable dose MTX ( 616 mg/week ) minimum 4 week prior screen visit Exclusion criterion : 1 . Autoimmune inflammatory systemic localize joint disease RA 2 . Women positive pregnancy test 3 . Latent active tuberculosis 4 . Prior treatment antiinterleukin6 ( antiIL6 ) antiinterleukin6 receptor ( IL6R ) antagonist 5 . Treatment antiTNF agent , follow : 1 . Etanercept : within 28 day prior randomization 2 . Infliximab , adalimumab , golimumab , certolizumab pegol : within 42 day prior randomization 6 . Received live , attenuated vaccine within 3 month prior randomization visit ( eg , varicellazoster , oral polio , rubella vaccine ) 7 . Significant concomitant illness , limited , cardiovascular , renal , neurological , endocrinological , gastrointestinal , hepatobiliary , metabolic , pulmonary lymphatic disease would adversely affect patient 's participation study . 8 . Received surgery within 4 week prior screen visit plan surgery study 9 . History systemic hypersensitivity reaction The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>